Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply.
作者信息
Vlaar Alexander P J, de Bruin Sanne, Brouwer Matthijs C, van de Beek Diederik
机构信息
Department of Intensive Care, Amsterdam UMC, University of Amsterdam, Amsterdam 1100DD, Netherlands.
Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, University of Amsterdam, Amsterdam 1100DD, Netherlands.
出版信息
Lancet Rheumatol. 2021 Feb;3(2):e95-e96. doi: 10.1016/S2665-9913(20)30424-0. Epub 2020 Dec 14.
Abstract
摘要
相似文献
1
Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply.疗效很重要：扩大新冠病毒肺炎中的补体抑制作用——作者回复
Lancet Rheumatol. 2021 Feb;3(2):e95-e96. doi: 10.1016/S2665-9913(20)30424-0. Epub 2020 Dec 14.
2
Efficacy matters: broadening complement inhibition in COVID-19.疗效至关重要：扩大对新冠病毒肺炎的补体抑制作用
Lancet Rheumatol. 2021 Feb;3(2):e95. doi: 10.1016/S2665-9913(20)30423-9. Epub 2020 Dec 14.
3
Safety and efficacy of the Russian COVID-19 vaccine: more information needed - Authors' reply.俄罗斯新冠疫苗的安全性与有效性：仍需更多信息——作者回复
Lancet. 2020 Oct 3;396(10256):e54-e55. doi: 10.1016/S0140-6736(20)31970-X. Epub 2020 Sep 21.
4
Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply.新型冠状病毒肺炎合并炎症反应过度患者的白细胞介素-1和白细胞介素-6抑制——作者回复
Lancet Rheumatol. 2021 Apr;3(4):e248-e249. doi: 10.1016/S2665-9913(21)00066-7. Epub 2021 Mar 8.
5
Authors' Reply: Safety and Efficacy of Bedside Peritoneal Dialysis Catheter Placement in the COVID-19 Era: Initial Experience at a New York City Hospital.作者回复：新冠疫情时代床边腹膜透析导管置入的安全性与有效性：纽约市一家医院的初步经验
World J Surg. 2020 Oct;44(10):3586. doi: 10.1007/s00268-020-05704-x. Epub 2020 Jul 29.
6
Vitamin D Deficiency: Definition Matters!: Authors' Reply.维生素D缺乏：定义很重要！作者回复
Indian Pediatr. 2020 Nov 15;57(11):1084.
7
Patient-reported outcomes: what really matters to patients? - Authors' reply.患者报告的结局：对患者真正重要的是什么？——作者回复
Lancet Oncol. 2022 May;23(5):e199. doi: 10.1016/S1470-2045(22)00216-9.
8
COVID-19 Vaccine in Children: Where Do We Stand?: Authors' Reply.儿童新冠疫苗：我们目前的进展如何？作者回复
Indian Pediatr. 2021 Feb 15;58(2):195.
9
Estimating vulnerability to COVID-19 in India - Authors' reply.
Lancet Glob Health. 2020 Dec;8(12):e1467. doi: 10.1016/S2214-109X(20)30429-0.
10
COVID-19 and the difficulty of inferring epidemiological parameters from clinical data - Authors' reply.新型冠状病毒肺炎与从临床数据推断流行病学参数的困难——作者回复
Lancet Infect Dis. 2021 Jan;21(1):28. doi: 10.1016/S1473-3099(20)30443-6. Epub 2020 May 28.
本文引用的文献
1
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.抗C5a抗体IFX-1（vilobelimab）治疗与最佳支持治疗对重症COVID-19患者的疗效比较（PANAMO）：一项探索性、开放标签的2期随机对照试验。
Lancet Rheumatol. 2020 Dec;2(12):e764-e773. doi: 10.1016/S2665-9913(20)30341-6. Epub 2020 Sep 28.
2
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.补体和组织因子富集的中性粒细胞细胞外陷阱是 COVID-19 免疫血栓形成的关键驱动因素。
J Clin Invest. 2020 Nov 2;130(11):6151-6157. doi: 10.1172/JCI141374.
3
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.COVID-19 炎症与 C5a-C5aR1 轴的激活有关。
Nature. 2020 Dec;588(7836):146-150. doi: 10.1038/s41586-020-2600-6. Epub 2020 Jul 29.
4
Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.控制疾病中的过敏毒素 C5a 需要有针对性的特异性抑制。
Clin Immunol. 2017 Jul;180:25-32. doi: 10.1016/j.clim.2017.03.012. Epub 2017 Mar 30.
Zotero 插件